This trial is evaluating whether Vincristine Sulfate will improve 5 primary outcomes and 3 other outcomes in patients with Medulloblastoma. Measurement will happen over the course of Up to 10 days.
This trial requires 26 total participants across 1 different treatment group
This trial involves a single treatment. Vincristine Sulfate is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Results from a recent paper provides a useful tool to parents and pediatricians working with children with brain tumors to assess the health status and possible manifestations of these cancers." - Anonymous Online Contributor
"Children's Hospitals' experience with treatment plans must be individualized on the basis of the children's age, tumor location and treatment history and their quality of life and physical demands." - Anonymous Online Contributor
"Medulloblastoma is extremely rare, but the number is being rapidly increasing in Western countries. There are few known environmental risk factors and the tumour-causing genetic alterations arise spontaneously in children. This cancer has two major clinical and biological subgroups that can have very different courses and results from therapy." - Anonymous Online Contributor
"Medulloblastoma is a brain tumor that typically forms in the cerebellum. It generally appears in children between the ages 2 and 5, and can be fatal. Medulloblastoma is a spectrum of neuronal tissue tumors that are most frequently malignant but can also be benign. This cancer is often treated with cranial irradiation and chemotherapy.\n" - Anonymous Online Contributor
"We conclude that current chemotherapy protocols in pediatric oncology are highly effective for treatment, yet not curative, irrespective of the stage of disease. In this patient population chemotherapy alone can be curative for a subset of patients with localized disease." - Anonymous Online Contributor
"The number of cases of medulloblastoma reported in the USA has increased in recent years. Although the reason for this remains unclear, there is no evidence of an increase in tumour age. Possible causes for the increase must be considered, including a greater sensitivity of detection by diagnostic investigations, earlier diagnosis, and early removal by surgery. In addition, the current OS was similar to those reported in other studies, while the incidence was almost double that of the UK, in contrast to a significantly higher rate of other childhood cancers." - Anonymous Online Contributor
"The newest drugs in vincristine are used to treat patients in a variety of malignancies including medulloblastoma. Vincristine is a chemotherapy drug that damages cells in the cell division cycle by blocking the ability of cells to produce DNA. The most commonly used dosage of vincristine sulfate is two to three milligrams per kilogram of body weight. Vincristine sulfate is sometimes given by intravenous infusion, but some newer forms of vincristine use a nasal spray to deliver the drug to the blood." - Anonymous Online Contributor
"Vincristine sulfate improves both QOL and PFS for children with newly diagnosed and refractory/recurrent medulloblastomas. Vincristine sulfate should be considered to improve the survival of these children." - Anonymous Online Contributor
"As the most common combination of vincristine sulfate is always infused concurrently with other drugs in pediatric patients, it is unlikely that our study design would adequately address the question of whether or not the additional treatment agents affect the toxicity and toxicity-related treatment-related adverse events of vincristine. However, the conclusions are of limited utility as vincristine sulfate may be used in isolation to treat children with medulloblastoma as part of a high-risk therapy regimen despite the fact that this does not result in any greater toxicity or risk of toxicity to other agents." - Anonymous Online Contributor
"In this population-based study we found only one other vincristine sulfate clinical trial that was not a phase III study and did not report any of the above favorable outcomes. Other clinical trialists interested in conducting a phase III randomized trial of the effects of vincristine sulfate may need to consider obtaining more information about the positive findings of the only other existing clinical trial." - Anonymous Online Contributor
"Current modalities are adequate and have enabled many patients with medulloblastoma to survive 2 or more years after the initial resection of the tumor. [Advances in surgery and radiotherapy are improving survival for this disease (medulloblastoma). In recent years, treatment using high-dose chemotherapy before surgery has increased the success of treatment and increased patients' survival compared with the older treatment approach (neoadjuvant chemotherapy followed by surgery). More recently, the use of postoperative radiotherapy has been demonstrated to provide additional benefit in reducing the risk of recurrence and prolonging progression-free survival [medulloblastoma.org/medulloblastoma]." - Anonymous Online Contributor
"The histological and molecular biology characteristics of medulloblastoma suggest rapid spread of the tumor to distant sites. In addition, we found no evidence of a tumor-specific survival disparity between children and adults." - Anonymous Online Contributor